Asset Details
Do you wish to reserve the book?
Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines
Do you wish to request the book?
Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines
2016
Overview
BackgroundNoonan syndrome with multiple lentigines (NSML), formerly known as LEOPARD syndrome, is an autosomal-dominant disorder characterised by lentigines, EKG abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, growth retardation and deafness. There is significant clinical overlap between NSML and other disorders that result from dysregulated rat sarcoma/mitogen-activated protein kinase pathway (RASopathies). Except for neurofibromatosis type 1, other RASopathies are not known to be typically associated with neurogenic tumours.Methods and resultsWe evaluated patients from three families with pigmentary skin lesions, progressive neuropathy, enlarged nerves, massive burden of paraspinal tumours (neurofibroma was confirmed in one patient) and a clinical diagnosis of NSML. All patients had a mutation in the protein tyrosine phosphatase catalytic domain of the PTPN11 gene; two unrelated patients had the p.Thr468Met mutation, while the family consisting of two affected individuals harboured the p.Thr279Cys mutation. Molecular analysis performed on hypertrophic nerve tissue did not disclose a second somatic hit in NF1, PTPN11, NF2 or SMARCB1 genes.ConclusionsNeurogenic tumours and hypertrophic neuropathy are unusual complications of NSML and may be an under-recognised manifestation that would warrant surveillance. Our observation may also have implications for other disorders caused by RAS-pathway dysregulation.
Publisher
BMJ Publishing Group LTD
Subject
/ Adult
/ Biopsy
/ Female
/ Genes
/ Humans
/ Kinases
/ Male
/ Mitogen-Activated Protein Kinases - genetics
/ Mitogen-Activated Protein Kinases - metabolism
/ Mutation
/ Neurofibromatosis 1 - etiology
/ Neurofibromatosis 1 - genetics
/ Patients
/ Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics
/ Tumors
